Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers

Abstract Angiogenesis, driven by the vascular endothelial growth factor (VEGF)/VEGFR signalling axis under hypoxic conditions, is one of the hallmarks of ovarian cancer (OC), contributing to tumour progression, metastatic dissemination and immune evasion. Hypoxia‐induced angiogenic signalling sustai...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Maria Rosaria Lamia, Erica Perri, Gustavo Baldassarre, Sandro Pignata, Chiara D'Alessio, Davide Limongello, Francesca Basso‐Valentina
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2026-01-01
Serie:	Clinical and Translational Medicine
Soggetti:	angiogenesis bevacizumab homologous recombination deficiency (HRD) ovarian cancer PARP inhibitors predictive biomarkers
Accesso online:	https://doi.org/10.1002/ctm2.70591
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!